Apollo Endosurgery (NASDAQ:APEN)‘s stock had its “buy” rating restated by equities research analysts at Northland Securities in a research report issued on Thursday. They currently have a $12.00 price target on the biotechnology company’s stock. Northland Securities’ price target would suggest a potential upside of 96.08% from the stock’s previous close.
The analysts wrote, “We note that the ASMBS Statement is not a guarantee of reimbursement for Orbera.””
Several other research firms have also recently commented on APEN. ValuEngine raised shares of Apollo Endosurgery from a “strong sell” rating to a “sell” rating in a research note on Wednesday, January 3rd. Roth Capital set a $10.00 target price on shares of Apollo Endosurgery and gave the company a “buy” rating in a research note on Thursday, January 4th. Finally, Zacks Investment Research cut shares of Apollo Endosurgery from a “buy” rating to a “hold” rating in a research note on Wednesday, December 27th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $9.44.
In other Apollo Endosurgery news, major shareholder Stonepine Capital, L.P. acquired 45,434 shares of the stock in a transaction dated Wednesday, December 20th. The shares were bought at an average price of $4.50 per share, with a total value of $204,453.00. Following the purchase, the insider now directly owns 2,410,141 shares of the company’s stock, valued at approximately $10,845,634.50. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders bought a total of 263,886 shares of company stock worth $1,288,051 in the last ninety days. Corporate insiders own 74.20% of the company’s stock.
Several institutional investors and hedge funds have recently made changes to their positions in APEN. Stonepine Capital Management LLC acquired a new position in shares of Apollo Endosurgery in the 3rd quarter worth approximately $11,067,000. King Luther Capital Management Corp acquired a new position in shares of Apollo Endosurgery in the 3rd quarter worth approximately $2,567,000. Russell Investments Group Ltd. acquired a new position in shares of Apollo Endosurgery in the 3rd quarter worth approximately $1,288,000. Woodmont Investment Counsel LLC acquired a new position in shares of Apollo Endosurgery in the 3rd quarter worth approximately $220,000. Finally, JPMorgan Chase & Co. acquired a new position in shares of Apollo Endosurgery in the 3rd quarter worth approximately $119,000. 23.67% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY WARNING: “Northland Securities Reaffirms “Buy” Rating for Apollo Endosurgery (APEN)” was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another site, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The legal version of this article can be read at https://www.americanbankingnews.com/2018/02/08/northland-securities-reaffirms-buy-rating-for-apollo-endosurgery-apen.html.
About Apollo Endosurgery
Apollo Endosurgery, Inc, formerly Lpath, Inc, is a medical device company. The Company is focused on less invasive therapies for the treatment of obesity, as well as other gastrointestinal disorders. The Company’s device-based therapies are an alternative to invasive surgical procedures. The Company offers products in over 80 countries.
Receive News & Ratings for Apollo Endosurgery Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollo Endosurgery and related companies with MarketBeat.com's FREE daily email newsletter.